Edesa Biotech (EDSA) Non-Current Debt (2021 - 2022)
Edesa Biotech (EDSA) posted Non-Current Debt of $43662.0 for Q3 2022, down 7.5% sequentially from $47202.0 in Q3 2021, and down 7.5% YoY from $47202.0 in Q3 2021.
Edesa Biotech (EDSA) Non-Current Debt (2021 - 2022) Analysis & Trends
Edesa Biotech has reported Non-Current Debt for 2 years, with the latest figure at $43662.0 in Q3 2022.
- Quarterly Non-Current Debt fell 7.5% year-over-year to $43662.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $43662.0 (down 7.5% YoY) and the FY2022 annual result came in at $43662.0, down 7.5% from the prior year.
- Non-Current Debt declined to $43662.0 in Q3 2022 per EDSA's latest filing, from $47202.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $47202.0 in Q3 2021 and troughed at $43662.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 8.96 Bn |
| 10 | Edesa Biotech | 42.25 Mn | 42.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 43,662.00 |
| Sep 30, 2021 | 47,202.00 |